Incyte (NASDAQ:INCY)‘s stock had its “buy” rating reaffirmed by Barclays in a research report issued on Sunday, AnalystRatings.com reports. They presently have a $90.00 price objective on the biopharmaceutical company’s stock. Barclays‘s target price points to a potential upside of 15.16% from the company’s previous close.

Other analysts have also recently issued reports about the company. Gabelli upgraded Incyte from a “hold” rating to a “buy” rating and set a $105.00 price target on the stock in a research note on Wednesday, January 23rd. Stifel Nicolaus began coverage on Incyte in a research note on Wednesday, April 10th. They issued a “hold” rating and a $82.00 price target on the stock. TheStreet upgraded Incyte from a “d+” rating to a “c-” rating in a research note on Friday, February 8th. BidaskClub upgraded Incyte from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 31st. Finally, Raymond James set a $100.00 price target on Incyte and gave the company a “buy” rating in a research note on Friday, February 15th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Incyte presently has a consensus rating of “Buy” and an average price target of $90.42.

NASDAQ:INCY opened at $78.15 on Friday. The firm has a market capitalization of $17.01 billion, a P/E ratio of 95.30 and a beta of 1.39. Incyte has a 12-month low of $57.00 and a 12-month high of $88.83. The company has a quick ratio of 4.29, a current ratio of 4.31 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY) last released its earnings results on Thursday, February 14th. The biopharmaceutical company reported $0.40 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.25 by $0.15. Incyte had a return on equity of 6.17% and a net margin of 5.82%. The firm had revenue of $528.40 million during the quarter, compared to analyst estimates of $485.72 million. During the same period last year, the business posted $0.02 earnings per share. Incyte’s revenue was up 19.0% compared to the same quarter last year. Equities research analysts predict that Incyte will post 1.27 earnings per share for the current year.

In other news, EVP Barry P. Flannelly sold 1,000 shares of Incyte stock in a transaction dated Monday, January 28th. The stock was sold at an average price of $80.00, for a total transaction of $80,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Paula J. Swain sold 10,000 shares of Incyte stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $87.01, for a total value of $870,100.00. Following the sale, the executive vice president now owns 38,295 shares in the company, valued at approximately $3,332,047.95. The disclosure for this sale can be found here. Insiders have sold 46,354 shares of company stock worth $3,820,424 in the last quarter. Insiders own 17.10% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of INCY. National Pension Service grew its holdings in shares of Incyte by 4.7% during the fourth quarter. National Pension Service now owns 222,084 shares of the biopharmaceutical company’s stock worth $18,526,000 after buying an additional 9,960 shares during the last quarter. Bank of Montreal Can grew its holdings in shares of Incyte by 20.4% during the fourth quarter. Bank of Montreal Can now owns 239,587 shares of the biopharmaceutical company’s stock worth $15,236,000 after buying an additional 40,525 shares during the last quarter. Bronfman E.L. Rothschild L.P. grew its holdings in shares of Incyte by 46.3% during the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 730 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 231 shares during the last quarter. Norinchukin Bank The grew its holdings in shares of Incyte by 45.2% during the fourth quarter. Norinchukin Bank The now owns 32,950 shares of the biopharmaceutical company’s stock worth $2,095,000 after buying an additional 10,256 shares during the last quarter. Finally, Standard Life Aberdeen plc grew its holdings in shares of Incyte by 12.3% during the third quarter. Standard Life Aberdeen plc now owns 46,161 shares of the biopharmaceutical company’s stock worth $3,189,000 after buying an additional 5,056 shares during the last quarter. Institutional investors and hedge funds own 91.59% of the company’s stock.

About Incyte

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Further Reading: Google Finance Portfolio Tips and Tricks

Analyst Recommendations for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.